Jiangsu Hengrui Pharmaceuticals Co.,Ltd (HKG:1276)

Market Cap	385.26B +11.2%
Revenue (ttm)	37.01B +11.6%
Net Income	9.23B +18.7%
EPS	1.39 +11.8%
Shares Out	n/a
PE Ratio	41.74
Forward PE	33.51
Dividend	0.23 (0.38%)
Ex-Dividend Date	Apr 29, 2026

Volume	3,420,536
Open	60.20
Previous Close	60.20
Day's Range	58.45 - 61.55
52-Week Range	53.55 - 95.20
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About HKG:1276

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 20,602
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1276

Financial Performance

In 2025, HKG:1276's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.

Financial numbers in CNY